Abstract
Decreased insulin sensitivity plays a major role in various human diseases, particularly type 2 diabetes mellitus, and is associated with a higher risk of atherosclerosis and cardiovascular complications. Thiazolidinediones, more commonly termed glitazones, are the first drugs to specifically target muscular insulin resistance. They have proven efficacy for reducing plasma glucose levels in patients with type 2 diabetes mellitus treated with diet alone, sulphonylureas, metformin or insulin. In addition, they are associated with some improvement of the cardiovascular risk profile. However, troglitazone, the first compound approved by the Food and Drug Administration in the US, proved to be hepatotoxic and was withdrawn from the market after the report of several dozen deaths or cases of severe hepatic failure requiring liver transplantation.
It remains unclear whether or not hepatotoxicity is a class effect or is related to unique properties of troglitazone. Rosiglitazone and pioglitazone, two other glitazones, appear to have similar efficacy with regard to blood glucose control in patients with type 2 diabetes mellitus as compared with troglitazone. In controlled clinical trials, the incidence of significant (≥3 × upper limit of normal) increases in liver enzyme levels (ALT in particular) was similar with rosiglitazone or pioglitazone as compared with placebo, whereas troglitazone was associated with a 3-fold greater incidence. In contrast to the numerous case reports of acute liver failure in patients receiving troglitzone, only a few case reports of hepatotoxicity have been reported in patients treated with rosiglitazone until now, with a causal relationship remaining uncertain. Furthermore, no single case of severe hepatotoxicity has been reported yet with pioglitazone. It should be mentioned that troglitazone, unlike pioglitazone and rosiglitazone, induces the cytochrome P450 isoform 3A4, which is partly responsible for its metabolism, and may be prone to drug interactions. Importantly enough, obesity, insulin resistance and type 2 diabetes mellitus are associated with liver abnormalities, especially non-alcoholic steatohepatitis, independent of any pharmacological treatment. This association obviously complicates the selection of patients who are good candidates for a treatment with glitazones as well as the monitoring of liver tests after initiation of therapy with any thiazolidinedione compound. While regular monitoring of liver enzymes is still recommended and more long term data are desirable, current evidence from clinical trials and postmarketing experience in the US supports the conclusion that rosiglitazone and pioglitazone do not share the hepatotoxic profile of troglitazone.
Similar content being viewed by others
References
Scheen AJ, Lefèbvre PJ. Pathophysiology of Type 2 diabetes. In: Kuhlmann J, Puls W, editors. Handbook of Experimental Pharmacology, Oral Antidiabtics. Springer Verlag: Berlin, 1996: 7–42
Chen Y-DI, Reaven GM. Insulin resistance and atherosclerosis. Diabetes Rev 1997; 5(4): 331–42
Scheen AJ, Lefèbvre PJ. Management of the obese diabetic patient. Diabetes Rev 1999; 7(2): 77-93
Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997 Sep; 54(3): 355–68
Gilbert RE, Cooper ME, Krum H. Drug administration in patients with diabetes mellitus. Safety considerations. Drug Saf 1998 Jun; 18(6): 441–55
Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996 Dec; 45(12): 1661–9
Grossman SL, Lessem J. Mechanisms and clinical effects of thiazolidinediones. Exp Opin Invest Drugs 1997; 6: 1025–40
Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am 1997 Sep; 26(3): 553–73
Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diab Med 1999 Mar; 16(3): 179–92
Scheen AJ, Paquot N, Letiexhe MR, et al. Les thiazolidinediones. In: Journées de diabétologie de l’Hôtel-Dieu, Flammarion. Paris: Médecine-Sciences, 1999: 213–29
Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000 Mar; 355: 1008–10
Bailey CJ. Insulin resistance and antidiabetic drugs. Biochem Pharmacol 1999; 58: 1511–20
Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998 Feb; 55(2): 225–36
Campbell IW. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs 2000 Nov; 60(5): 1017–28
Spiegelman BM. PPAR-g adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507–14
Spencer CM, Markham A. Troglitazone. Drugs Jul 1997; 54(1): 89–101
Chen C. Troglitazone: an antidiabetic agent. Am J Health Syst Pharm 1998 May; 55(9): 905–25
Johnson MD, Campbell LK, Campbell RK. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann Pharmacother 1998 Mar; 32(3): 337–48
Plosker GL, Faulds D. Troglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 1999 Mar; 57(3): 409–38
Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone [letter]. N Engl J Med 1998 Mar; 338(13): 916–7
Kohlroser J, Mathai J, Reichheld J, et al. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000 Jan; 95(1): 272–6
Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999 Jun; 57(6): 921–30
Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000 Aug; 60(2): 333–43
Bailey CJ. Rosiglitazone and pioglitazone: two new thiazolidinediones. Pract Diab Int 2000 Jul/Aug; 17(5): 135–7
Bankhead C. Not all glitazone tarnished by hepatotoxicity. Inpharma 2000 Aug; 1249: 19–20
Van Gaal L, Scheen AJ, editors. Are all glitazones the same? Satellite symposium of the EASD 1999. Diabetes/Metab Rev Res, 2001 (Suppl.). In press
Daniel K. The glitazones: proceed with caution. West J Med; 2000 Jul; 173(1): 54–7
Tolman KG. Thiazolidinedione hepatotoxicity: a class effect? IJCP 2000 Oct; Suppl. 113: 29–34
Petrides AS. Liver disease and diabetes mellitus. Diabetes Rev 1994; 2: 2–18
Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137–45
Ludwig J, McGill DB, Lindor KD. Review: Non alcoholic steatohepatitis. J Gastroenterol Hepatol 1997; 12: 398–403
James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495–501
Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19: 221–9
Luyckx FH, Lefèbvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diab Metab 2000; 26: 98–106
Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis 1970; 3: 371–407
Stone BG, Van Thiel DH. Diabetes mellitus and the liver. Semin Liver Dis 1985; 5: 8–28
Salmela PI, Sotaniemi EA, Niem M, et al. Liver function tests in diabetic patients. Diabetes Care 1984; 7: 248–54
Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med 2000 Nov; 109(7): 588–90
Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obesity 1995; 19Suppl. 3: S27–36
Zimmerman HJ, MacMurray FG, Rappaport H, et al. Studies of the liver in diabetes mellitus II. The significance of fatty metamorphosis and its correlation with insulin insensitivity. J Lab Clin Med 1950; 36: 922–7
Nagore N, Scheuer PJ. The pathology of diabetic hepatitis. J Pathol 1998; 156: 155–60
Wanless IR, Lentz JS. Fatty liver steatosis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106–0
Silverman JF, O’Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85: 1349–55
Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9
Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C infection. Hepatology 1999; 29: 328–3
Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000 Oct; 133(8): 592–9
Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999 Dec; 22(12): 2067–71
Dossing M, Sonne J. Drug-induced hepatic disorders: incidence, management and avoidance. Drug Safety 1993; 9: 441–9
Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333: 1118–27
Benicho C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11: 272–6
Meyboom RH, Hekster YA, Egberts AC, et al. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Safety 1997; 17: 374–89
Michalets EL. Update: clinically significant cytochrome P 450 drug intercations. Pharmacotherapy 1998; 18: 84–112
Yamazaki H, Suzuki M, Tane K, et al. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica 2000 Jan; 30(1): 61–70
Scheen AJ, Lefèbvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999 Sep; 22(9): 1568–77
Wise J. Diabetes drug withdrawn after reports of hepatic events. BMJ 1997; 315(7122): 1564
Wageaar LJ, Kuck EM, Hoekstra JB. Troglitazone. Is it all over? Neth J Med 1999 Jul; 55(1): 4–12
Bailey CJ. The rise and fall of troglitazone. Diabet Med 2000; 17: 414–5
Liver damage warnings for troglitazone. Scrip 1997 Nov; 7 (2282): 21
Call to ban troglitazone in US. Scrip 1998 Jul; 31 (2357): 22
Ault A. Troglitazone ban loses support. Lancet 1999; 353: 1161
Food and Drug Administration. FDA Talk paper. Washington, DC: US Department of Health and Human Services; March 21, 2000
Gitlin N. Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998 Jul; 129(1): 36–8
Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 1998 Jul; 129(1): 38–41
Shibuya A, Watanabe M, Fujita Y, et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 1998 Dec; 21(12): 2140–3
Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone [letter]. Ann Intern Med 1998 Dec; 129(12): 1080
Neuschwander-Tetri BA, Isley WL, Oki JC. Troglitazone-associated hepatic failure [letter]. Ann Intern Med 1999 Feb; 130(4): 330
Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone [letter]. Ann Intern Med 1999 Jan; 130(2): 163
Misbin RI. Troglitazone-associated hepatic failure [letter]. Ann Intern Med 1999 Feb; 130(4): 330
Iwase M, Yamaguchi M, Yoshinari M, et al. A Japanese case of liver dysfunction after 19 months of troglitazone treatment [letter]. Diabetes Care 1999 Aug; 22(8): 1382–4
Jogannath S, Rai R. Rapid-onset subfulminant liver failure associated with troglitazone [letter]. Ann Intern Med 2000 Apr; 132(8): 677
Fukano M, Amano S, Sato J, et al. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Hum Pathol 2000 Feb; 31(2): 250–3
Malik AH, Prasad P, Saboorian MH, et al. Hepatic injury due to troglitazone. Dig Dis Sci 2000 Jan; 45(1): 210–4
Murphy EJ, Davern TJ, Shakil AO, et al. Troglitazone-induced fulminant hepatic failure. Dig Dis Sci 2000 Mar; 45(3): 549–3
Schiano T, Dolehide K, Hart J, Baker AL. Severe but reversible hepatitis induced by troglitazone. Dig Dis Sci 2000 MAy; 45(5): 1039–42
Booth AM, Caldwell SH, Iezzoni JC. Troglitazone-associated hepatic failure. Am J Gastroenterol 2000 Feb; 95(2): 557–8
Prendergast KA, Berg CL, Wisniewski R. Troglitazone-associated hepatotoxicity treated successfully with steroids [letter]. Ann Intern Med 2000 Nov; 133(9) 751
Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000 Aug; 133(4): 263–74
Kuramoto K, Shimizu N, Toda G. Liver dysfunction associated with troglitazone (Noscal) [in Japanese]. Rinsho Iyaku 1998; 14: 461–6
Ogata E, Yamada Y, Iga R. Liver dysfunction due to troglitazone [in Japanese]. Naika 1999; 83: 534–9
Toyota T, Ueno Y. Clinical effect and side effect of troglitazone [in Japanese]. Nippon Rinsho 2000 Feb; 58(2): 376–82
Riddle MC. Learning to use troglitazone. Diabetes Care 1998; 21: 1389–90
Imura H. A novel antidiabetic drug, troglitazone - reason for hope and concern [editorial]. N Engl J Med 1998 Mar; 338(13): 908–9
Graham DJ, Drinkard CR, Shati D, Tson Y, Burgess MJ. Liver enzyme monitoring in patient treated with troglitazone. JAMA 2001 Aug; 286: 831–3
Zimmerman HJ, Ishak KG. Hepatic injury due to drugs and toxins. In: MacSween RNM, Anthony PP, Scheuer PJ, et al. editors. Pathology of the liver. 3rd ed. London: Churchill Livingstone, 1994: 563–633
Loi CM, Alvey CW, Randinitis EJ, et al. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 1997; 37: 1038–47
Loi C-M, Young M, Randinitis E, et al. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 1999 Aug; 37: 91–104
Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency. Eur J Clin Pharmacol 1998 Sep; 54(7): 567–71
Young MA, Lettis S, Eastmond R. Co-administration of acetaminophen and troglitazone: Pharmacokinetics and safety. J Clin Pharmacol 1998; 38(Suppl. 9): 819–25
Izumi I, Hosiyama K, Enomoto S, et al. Pharmacokinetics of troglitazone, an antidiabetic agent: Prediction of in vivo stereo-selective sulphation and glucuronidation from in vitro data. J Pharmacol Exptl Therap 1997 Mar; 280(3): 1392–400
Kawai K, Kawasaki-Tokui Y, Odaka T, et al. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittel-Forschung 1997 Apr; 47(4): 356–68
Yamazaki H, Shibata A, Suzuki M, et al. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 1999; 27: 1260–6
Ramachandran V, Kostrubsky VE, Komoroski BJ, et al. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab Disp 1999 Oct; 27(10): 1194–9
Sahi J, Hamilton G, Sin M et al. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 2000 Mar; 30: 273–84
Peter JV, Neafus KL, Khan MA, et al. Factors associated with the risk of liver enzyme elevation in patients with type 2 diabetes treated with a thiazolidinedione. Pharmacotherapy 2001 Feb; 21: 183–8
Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001 Apr; 33: 1009–13
Inoue I, Katayama S, Takahashi K, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Comm 1997; 235: 113–6
Kassahun K, Pearson PG, Tan W et al. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 2001 Jan; 14: 62–70
Guillouzo A, Morel F, Langouet S, et al. Use of hepatocyte cultures for the study of hepatotoxicity compounds. Toxicology 1997; 82(Suppl. 1-3): 209–19
Kostrubsky VE, Sinclair JF, Ramachandran V, et al. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab Disp 2000 Oct; 28(10): 1192–7
Elcock FJ, Lyon JJ, Hitchcock J, et al. Toxicity of troglitazone in cultured rat hepatocytes [abstract]. Diabetes 1999; 48Suppl. 1: A63
Funk C, Ponelle C, Scheuermann G, et al. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001 Mar; 59: 627–35
Galli EL, Crabb D. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 2000 Jun; 20(3): 191–9
Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrinogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000 Aug; 119(2): 466–78
Jia DM, Tabaru A, Akiyama T, et al. Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol 2000 Oct; 15(10): 1183–91
Scheen AJ. Thiazolidinediones and liver toxicity. Diab Metab 2001; 27: 305–13
Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001 Feb; 96: 519–25
Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001 Jun; 357:1870-5
Goldstein BJ. Rosiglitazone. Int J Clin Pract 2000 Jun; 54(5): 333–7
Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 22(10): 1151–68
Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week randomized, placebo controlled study. Diabetes Obesity Metab 1999; 1: 165–72
Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone shortterm monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000 Mar; 43(3): 278–84
Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabet Med 2000 Apr; 17(4): 287–94
Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000 Jan; 17(1): 40–7
Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 2000 Apr; 283(13): 1695–702
Salzman A, Patel J. Rosiglitazone is not associated with hepatotoxicity [abstract]. Diabetes 1999; 48Suppl. 1: A95
Lebovitz HE, Salzman A. Rosiglitazone liver safety update [abstract]. Diabetes 2000; 49Suppl. 1: A39
Buckingham RE, Birmingam J, O’Brien P, et al. Rapid reversal of hepatic steatosis by rosiglitazone [abstract]. Diabetologia 2001 Sep; 44Suppl. 1: A200
Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000 Jan; 132(2): 118–21
AI-Salman J, Arjomand H, Kemp D, et al. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med 2000 Jan; 132(2): 121–4
Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure [letter]. Ann Intern Med 2000 Jan; 132(2): 164
Isley WL, Oki JC. Rosiglitazone and liver failure. Ann Intern Med 2000 Sep; 133(5): 393–4
Ravinuthala RS, Nori U. Rosiglitazone toxicity [letter]. Ann Intern Med 2000 Oct; 133: 658
Canada reports 166 ADRs with Avandia. Scrip 2001 Aug; 2668: 23
Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28(7): 772–80
Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999 Sep; 48(3): 424–32
Thompson KA, Miller AK, Inglis AML, et al. Rosiglitazone does not markedly alter CYP3A4-mediated drug metabolism [abstract]. Diabetologia 1999; 42Suppl. 1: A227
Klotz U, Sailer D. Arzneimittelinteraktionen - ihre Bedeutung für eine sichere Therapie am Beispiel der neuen Wirkstoffgruppe der Thiazolidindione (Glitazone). Arzneim-Forsch/Drug Res 2001 Jan; 51: 112–7
Miller AK, Inglis AL, Thompson K, et al. Effect of hepatic impairment on the pharmacokinetics of rosiglitazone [abstract]. Clin Pharmacol Ther 1999; 65: PIII–37
New drug overview. Pioglitazone hydrochloride. Am J Health Syst Pharm 2000; 57: 124–5
Aronoff S, Rosenblatt S, Braithwaite S, et al. for The Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000 Nov; 23(11): 1605–1
Einhorn D, Rendell M, Rosenzweig J, et al. for The Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study Clin Ther 2000; 22: 1395–409
Rubin C, Schneider R. Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials [abstract]. Diabetes 2000; 49Suppl. 1: A123
Belcher G, Matthews DR. Safety and tolerability of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108Suppl. 2: S267–73
Weinstock RS, Murray FT, Diani A, et al. Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. Pharmacology 1997 Apr; 54(4): 169–78
Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108Suppl. 2: S234–42
Glazer NB, Cheatham WW. Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4 [letter]. BMJ 2001 Jan; 322: 235–6
Aoyama E, Tsujiuchi H, Asahi S, Yamashita K, Yoshimura Y. In vitro studies on the metabolic pathways of pioglitazone [abstract]. Diabetes 2001 Jun; 50(Suppl 1): A105
Kortboyer JM, Eckland D. Pioglitazone has low potential for drug interactions [abstract]. Diabetologia 1999 Aug; 42Suppl. 1: A228
Acknowledgements
The author has no financial links of any sort with the manufacturers of the thiazolidinediones or with potential competitors in this drug class.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scheen, A.J. Hepatotoxicity with Thiazolidinediones. Drug-Safety 24, 873–888 (2001). https://doi.org/10.2165/00002018-200124120-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200124120-00002